

# Introduction to BonAlive Biomaterials Ltd



12 April 2010

# BonAlive Biomaterials Ltd

## Facility and location

Headquarters in Turku, Finland

Total space: 475 M<sup>2</sup>

Clean rooms manufacturing: 65 M<sup>2</sup>



# Introduction to BonAlive Biomaterials Ltd.


Core purpose:	To become the world-leader in providing biomaterial solutions for the treatment of chronically infected bone
Research and Development:	Strong pipeline with new innovations
Manufacturing:	All manufacturing is performed in Turku, Finland
Sales and Marketing:	Active in 12 countries in Europe, Middle East, Americas and Asia/Pacific
Product registrations:	2004 / CE-mark for BonAlive® cranio-maxillofacial surgery 2006 / CE-mark for BonAlive® orthopedic surgery 2008 / 510k for CMF, orthopedic and dental surgery
Certified Quality System:	DS/EN ISO 13485:2003 DS/EN ISO 9001:2008 FDA QSR implemented




# BonAlive<sup>®</sup> granules

- Naturally inhibits bacterial growth (**UNIQUE FEATURE**)
- Bioactive (bonds chemically to bone)
- Stimulates new bone formation (**Osteostimulation**)
- Forms natural bone through constant remodeling
- Biocompatible (Safe)
- Clinical use: >15 years proven performance
- Fully synthetic and biodegradable:
  - SiO<sub>2</sub> 53%, Na<sub>2</sub>O 23%, CaO 20%, P<sub>2</sub>O<sub>5</sub> 4% (by weight)

BonAlive in **Orthopaedics** and  
**cranio-maxillofacial** surgery




**BENIGN BONE TUMOURS**



**FRACTURES**



**SPONDYLODESIS**



# BonAlive® "Easy to Use" Package

## Package sizes:

- 5 cc
- 10 cc

## Granule sizes:

- 0.5-0.8 mm (Small)
- 1.0-2.0 mm (Medium)
- 2.0-3.15 mm (Large)

